BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca

Second novel target for idiopathic pulmonary fibrosis was discovered using BenevolentAI's drug discovery platform and selected for AstraZeneca's drug development portfolio A total of three targets have been selected for portfolio-entry in the collaboration to date, with the potential to...